title: Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.
abstract: BACKGROUND
  Serum LH levels decrease with increasing body mass index (BMI) in women with polycystic ovarian syndrome (PCOS).
  
  
  OBJECTIVE
  The objective of this study was to determine whether pharmacokinetic factors contribute to the effect of obesity on LH in PCOS. PARTICIPANTS/INTERVENTIONS/SETTING: Twenty-one women with PCOS underwent frequent blood sampling, iv administration of GnRH (75 ng/kg), and sc administration of the NAL-GLU GnRH antagonist (150 microg/kg) followed by iv recombinant human LH (rhLH; 300 IU) in the General Clinical Research Center at an academic medical center.
  
  
  METHODS
  Pharmacokinetic parameters were estimated by modeling the LH serum concentration profiles after administration of GnRH and rhLH and related to BMI.
  
  
  RESULTS
  Serum levels of LH and rhLH decreased in a distinctly monoexponential fashion in all patients. The apparent biological half-life of rhLH was not influenced by BMI, nor was the total body clearance or apparent volume of distribution. However, the apparent half-life of endogenous LH was inversely related to BMI (r=-0.46; P<0.04), and the estimated total body clearance of endogenous LH was positively related to BMI (r=0.53; P<0.02).
  
  
  CONCLUSIONS
  Estimated clearance and apparent half-life of endogenous LH are influenced by BMI in women with PCOS, contributing to the inverse relationship between LH and BMI in this population. The absence of an effect of BMI on the pharmacokinetics of rhLH in these subjects suggests that the effect of obesity on clearance of endogenous LH is the result of alterations in the isoform composition of LH secreted by the pituitary.
authors.affiliation: Reproductive Endocrine Unit, BHX-5, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA.
authors.forename: Serene S
authors.initials: SS
authors.lastname: Srouji
authors.forename: Yanira L
authors.initials: YL
authors.lastname: Pagán
authors.forename: Fernando
authors.initials: F
authors.lastname: D'Amato
authors.forename: Amsalu
authors.initials: A
authors.lastname: Dabela
authors.forename: Yarisie
authors.initials: Y
authors.lastname: Jimenez
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Supko
authors.forename: Janet E
authors.initials: JE
authors.lastname: Hall
mesh_terms: D015992:Body Mass Index; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood* / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000503:physiopathology*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone